Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Berger

Showing results (51-60 of 134) with videos related to

Pageof 14
Sort By:
International Clinical Psychopharmacology|July 1, 1986
Improvement of symptoms in Tourette syndrome by piquindone, a novel dopamine-2 receptor antagonistS B Uhr, B Pruitt, P A Berger, et al.
Research Publications - Association for Research in Nervous and Mental Disease|January 1, 1986
Investigating opioid peptides in schizophrenia and depressionP A Berger, S J Watson, H Akil, et al.
Psychopharmacology Bulletin|October 1, 1982
Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in cognitively impaired patientsJ R Tinklenberg, R Pigache, P A Berger, et al.
Neurobiology of Aging|July 1, 1986
Desamino-D-arginine-vasopressin (DDAVP) in Alzheimer's diseaseC A Peabody, H Davies, P A Berger, et al.
Annals of Neurology|March 1, 1989
Cerebrospinal fluid monoamine metabolites in narcolepsy: reanalysisK F Faull, C Guilleminault, P A Berger, et al.
Psychopharmacology Bulletin|July 1, 1979
Prospects for the evaluation of endorphins as psychotropic agentsP A Berger, S J Watson, H Akil, et al.
Annals of Neurology|March 1, 1983
Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomniaK F Faull, C Guilleminault, P A Berger, et al.
The American Journal of Psychiatry|July 1, 1981
The effects of naloxone in chronic schizophreniaP A Berger, S J Watson, H Akil, et al.
Archives of General Psychiatry|January 1, 1982
Impaired central error-correcting behavior in schizophreniaR C Malenka, R W Angel, B Hampton, et al.
The Yale Journal of Biology and Medicine|November 1, 1985
Peptide neuroregulators: the opioid system as a modelJ D Barchas, C Evans, G R Elliott, et al.
Pageof 14

Showing results (51-60 of 134) with videos related to

Sort By:
Pageof 14
International Clinical Psychopharmacology|July 1, 1986
Improvement of symptoms in Tourette syndrome by piquindone, a novel dopamine-2 receptor antagonistS B Uhr, B Pruitt, P A Berger, et al.
Research Publications - Association for Research in Nervous and Mental Disease|January 1, 1986
Investigating opioid peptides in schizophrenia and depressionP A Berger, S J Watson, H Akil, et al.
Psychopharmacology Bulletin|October 1, 1982
Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in cognitively impaired patientsJ R Tinklenberg, R Pigache, P A Berger, et al.
Neurobiology of Aging|July 1, 1986
Desamino-D-arginine-vasopressin (DDAVP) in Alzheimer's diseaseC A Peabody, H Davies, P A Berger, et al.
Annals of Neurology|March 1, 1989
Cerebrospinal fluid monoamine metabolites in narcolepsy: reanalysisK F Faull, C Guilleminault, P A Berger, et al.
Psychopharmacology Bulletin|July 1, 1979
Prospects for the evaluation of endorphins as psychotropic agentsP A Berger, S J Watson, H Akil, et al.
Annals of Neurology|March 1, 1983
Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomniaK F Faull, C Guilleminault, P A Berger, et al.
The American Journal of Psychiatry|July 1, 1981
The effects of naloxone in chronic schizophreniaP A Berger, S J Watson, H Akil, et al.
Archives of General Psychiatry|January 1, 1982
Impaired central error-correcting behavior in schizophreniaR C Malenka, R W Angel, B Hampton, et al.
The Yale Journal of Biology and Medicine|November 1, 1985
Peptide neuroregulators: the opioid system as a modelJ D Barchas, C Evans, G R Elliott, et al.
Pageof 14